RYZ101 — Investigational Agent
Radiopharmaceutical · Phase 3 · RayzeBio (Bristol Myers Squibb)
Mechanism of Action
An actinium-225 labeled somatostatin analog delivering high-linear-energy alpha-particle radiation to SSTR2-expressing neuroendocrine tumor cells, producing dense double-strand DNA breaks over a short tissue range.
Investigational Indications
- SSTR-positive gastroenteropancreatic neuroendocrine tumors progressing after ¹⁷⁷Lu-based therapy